Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mentor™4: catridecacog PK and safety in children 1 to <6 years
NCT01230021Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2010
- Primary completion
- Jan 2012
- Countries
- 3
01
Overview
Phase 3, open-label trial of catridecacog, sponsored by Novo Nordisk. Primary endpoint: Area Under the Concentration vs. Time Curve at 30 days. Started Nov 2010; status: completed.
02
Drugs
catridecacog
Beyond the preview
Go deeper on NCT01230021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230021.